Launch of an ES/CS Service for Medical Institutions
First written in FY2017-Q1. 10 of 17 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022DroppedAnnual report
「January 2022: Liquidation of the consolidated subsidiary ㈱Vメディカル」
The liquidation of the subsidiary responsible for the former publishing and ES/PS services for medical institutions was recorded, completing the exit from those services. - FY2021ReframedAnnual report
「April 2020: Transfer of the publishing and ES/PS survey services of the consolidated subsidiary ㈱バリューメディカル」
The Company shifted from launching and expanding publishing and ES/PS services for medical institutions to transferring those businesses and focusing the medical business on supplements. - FY2021-Q1ReframedAnnual report
「In the medical business, the Company advanced restructuring to improve profitability, which had been an issue. For the less profitable services, namely the book publishing service and the ES/PS employee and patient satisfaction survey service, it entered into an agreement concerning the transfer of the businesses. In parallel, it reviewed personnel allocation and the cost structure and focused on establishing an operating structure capable of generating stable earnings.」
The policy shifted from expanding the existing ES/PS service to improving profitability by transferring the low-profitability book publishing and ES/PS services and reviewing personnel and the cost structure. - FY2020-Q3AdvancedAnnual report
「In the medical business, the Company continued sales activities for the publishing and ES/PS services and conducted sales promotions, including announcing a 2-month free trial monitor program for “Stable UC-Ⅱ,” the supplement focused on anti-aging and locomotive syndrome (musculoskeletal dysfunction) that was launched in May.」
The Company continued sales activities for the ES/PS and publishing services and advanced sales promotions for “Stable UC-Ⅱ,” including announcing a 2-month free trial monitor program. - FY2020-Q2AdvancedAnnual report
「The product was developed as part of a business synergy project launched in response to feedback from members acquired through the golf business who wanted to remain healthy enough to play golf indefinitely. Promotion was therefore initially limited to those members. After gaining confidence in expanding services related to health and pre-emptive healthcare, the Company expanded the promotional target and began selling the product to non-members as well.」
The Company expanded the target of supplement promotions, which had been limited to golf members, and began selling the product to non-members. - FY2020-Q1AdvancedAnnual report
「In the medical business, the ES/PS service secured recurring orders from numerous medical institutions and continued to perform steadily. In response to feedback from golfer members in the golf business who wanted to remain healthy enough to play golf indefinitely, the Company completed development of the supplement “Stable UC-Ⅱ,” focused on anti-aging and locomotive syndrome (musculoskeletal dysfunction). The product was launched on 15 May 2019, but upfront costs, including advertising and promotional expenses incurred in preparation for sales, temporarily arose.」
The ES/PS service secured recurring orders, and development of the supplement for anti-aging and locomotive syndrome was completed and the product was launched on 15 May 2019. - FY2019AdvancedAnnual report
「The new ES/PS service, an employee and patient satisfaction survey service, received favorable evaluations from hospitals where surveys were conducted and achieved results as expected, including securing orders to conduct surveys in the following fiscal year. The Company also focused on anti-aging and locomotive syndrome (musculoskeletal dysfunction) based on feedback from golfer members held by the Group and began developing supplements.」
The ES/PS service secured repeat orders for the following fiscal year, and the Company also began developing supplements as its next service. - FY2019-Q3AdvancedAnnual report
「In the medical business, alongside sales activities for existing services, the Company developed supplements for its new anti-aging and locomotive syndrome (musculoskeletal dysfunction) service.」
Development progressed on supplements for anti-aging and locomotive syndrome as a new service following the ES/PS and publishing services. - FY2019-Q2AdvancedAnnual report
「In the medical business, the Company continued to pursue new orders for the employee and patient satisfaction survey service, the ES/PS service, and the publishing service. Delivery of projects in progress was postponed until the following quarter due to repeated natural disasters, including torrential rain in western Japan and typhoons. The Company also made an upfront investment to develop a third service following the ES/PS and publishing services.」
While continuing to pursue new projects for the ES/PS and publishing services, the Company began upfront investment in developing a third service following those two services. - FY2019-Q1AdvancedAnnual report
「In the medical business, the Company worked to secure new orders for the employee and patient satisfaction survey service, the ES/PS service, and the publishing service, focusing on securing sufficient orders to underpin performance for the current fiscal year. Because it delivered projects already under order through the employee and patient satisfaction survey service, sales increased substantially year on year.」
The Company delivered projects already under order through the ES/PS service and worked to secure new projects and orders together with the publishing service. - FY2018-Q3AdvancedAnnual report
「In the medical business, delivery of the employee and patient satisfaction survey service, the ES/PS service, commenced. In addition to repeat orders from a municipal hospital that had conducted a pilot version the previous year, requests for surveys, primarily from university hospitals, increased steadily. The publishing service performed strongly, publishing 1 edition in the third quarter and securing new orders from a newly acquired public hospital.」
Following the start of delivery of the ES/PS service, repeat orders from municipal hospitals and survey requests from university hospitals increased. The publishing service published 1 edition in the third quarter and secured a new order from a public hospital. - FY2018-Q2AdvancedAnnual report
「In the medical business, delivery of the employee and customer satisfaction survey service, the ES/CS service, commenced, formally launching the introduction of the new service that had been developed since the previous fiscal year. The publishing service performed strongly, publishing 4 editions and securing new orders from national and private hospitals.」
In addition to commencing delivery of the ES/CS service, the Company published 4 editions through its publishing service and secured new orders from national and private hospitals. - FY2018-Q1AdvancedAnnual report
「In the medical business, delivery of the employee and customer satisfaction survey service, the ES/CS service, commenced, formally launching the introduction of the new service that had been developed since the previous fiscal year.」
Delivery of the ES/CS service, which had been in the preparation and formal-launch stages, commenced, marking the start of its actual operation. - FY2017RestatedAnnual report
「The Company invested in the new ES/CS service for medical institutions and formally launched it, while working to increase new contracts through synergies with the publishing service.」
Following the formal launch of the ES/CS service, the Company is continuing to target an increase in new contracts through synergies with the publishing service. - FY2017-Q3RestatedAnnual report
「In the medical business, the Company invested in the new ES/CS service for medical institutions and formally launched it, while working to increase new contracts through synergies with the publishing service.」
Following the formal launch of the ES/CS service for medical institutions, efforts to increase new contracts through synergies with the publishing service have continued. - FY2017-Q2AchievedAnnual report
「The Company invested in the new ES/CS service for medical institutions and formally launched it, while working to increase new contracts through synergies with the publishing service.」
The ES/CS service for medical institutions, which was under preparation in the previous quarter, was formally launched. Increasing new contracts through synergies with the publishing service remains an ongoing challenge. - FY2017-Q1First statedAnnual report
「In the medical business, although delivery under the publishing service was limited to 1 project, preparations for the launch of the new service for medical institutions, the ES/CS service, progressed smoothly, and efforts were focused on launching it as soon as possible.」
Preparations are under way to launch a new service for medical institutions, with an early start targeted.